AIRS

AirSculpt Technologies, Inc. (AIRS) - Q3 2025 10-Q Summary

Business Context and Reporting Period

AirSculpt Technologies, Inc. is a provider of practice management services for professional associations offering minimally invasive liposuction and body contouring procedures. The company operates 31 centers across 20 U.S. states and Canada as of November 2025. This report covers the quarterly period ended September 30, 2025. The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Liquidity: As of September 30, 2025, the company held $5.4 million in cash and cash equivalents with $5.0 million available under its revolving credit facility. The company reported a working capital deficit of $11.9 million.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 17.8% year-over-year in Q3 and 16.1% for the nine-month period. This was driven by a 15.2% decline in total cases performed (2,780 cases in Q3 2025 vs. 3,277 in Q3 2024) and weaker performance in the broader aesthetics industry.
• Impairment Charges: The company recorded a $7.1 million loss on impairment of long-lived assets in Q3 2025. This included a $4.6 million charge for a partially completed Salesforce implementation project and a $2.3 million charge related to the planned closure of its London facility.
• Cost Reductions: Selling, general, and administrative (SG&A) expenses decreased 23.4% in Q3, driven by reduced advertising spend, lower stock compensation, and legal costs, partially offset by $1.0 million in accelerated rent amortization for the London facility.
• Debt Repayment: The company utilized proceeds from a June 2025 equity offering to make a $10.0 million principal payment on its term loan, reducing total debt from $69.7 million to $56.9 million.

Guidance, Outlook, and Risks

Management Commentary: Management has announced strategic initiatives to stabilize revenue, including optimizing marketing investments, improving go-to-market strategies, and enhancing customer experience. A cost reduction program is estimated to eliminate $3.0 million in annual overhead costs. The company has paused the opening of new centers and procedure rooms.

Outlook: The company expects to finalize the liquidation of the London facility in Q4 2025. It anticipates completing the remaining portion of its Salesforce project in Q1 2026. Management believes cash from operations will be sufficient for working capital and debt service for at least the next 12 months.

Risks and Contingencies:

• Debt Covenants: The company amended its credit agreement in March 2025 to modify financial covenants, including a minimum liquidity requirement of $7.5 million starting May 2025. Interest rates on the credit facility increased effective July 2025 based on leverage ratios.
• Market Competition: Increased competition from weight-loss drugs and other obesity solutions poses a risk to demand.
• Legal: The company faces routine medical malpractice claims, though it maintains insurance coverage.

Investor Verification Checklist

• Revenue Trajectory: Verify if the 15%+ decline in case volume is stabilizing or accelerating in Q4, given the competitive pressure from weight-loss drugs.
• Liquidity Compliance: Confirm the company maintains the $7.5 million minimum liquidity covenant required by its amended credit agreement.
• Impairment Finality: Assess if the $7.1 million impairment charge represents a one-time event or if further write-downs are likely regarding the Salesforce project or other assets.
• Cost Savings Realization: Monitor the actual realization of the estimated $3.0 million in annual cost savings from the reduction program.
• Equity Dilution: Review the impact of the June 2025 follow-on offering and the active At-The-Market (ATM) program on shareholder dilution.